Theodore E. Warkentin, MD; Paul Kwon, MD
Potential Financial Conflicts of Interest: Employment: P. Kwon (Genentech); Consultancies: T.E. Warkentin (Genentech); Stock ownership: P. Kwon (Genentech).
Warkentin TE, Kwon P. Immune Thrombocytopenia Associated with Efalizumab Therapy for Psoriasis. Ann Intern Med. 2005;143:761-763. doi: 10.7326/0003-4819-143-10-200511150-00028
Download citation file:
Published: Ann Intern Med. 2005;143(10):761-763.
TO THE EDITOR:
Background: Efalizumab is a recombinant humanized anti-CD11a monoclonal IgG1 antibody. Efalizumab recognizes the α-subunit of leukocyte function-associated antigen type 1, thereby blocking interaction between the antigen and intercellular adhesion molecules and associated signaling and T-cell migration (1). The agent is licensed for the treatment of moderate to severe plaque psoriasis (2).
Objective: To describe the frequency, clinical features, and response to treatment of putative immune-mediated thrombocytopenia during efalizumab treatment.
Methods: During the efalizumab clinical development program, 2762 patients were treated with the drug. We reviewed the case files of all patients with thrombocytopenia (classified by investigators as a “serious adverse event”) or those whose platelet count decreased to less than 50 × 109 cells/L. Eight patients meeting these criteria were evaluated; in 2 of these, thrombocytopenia was judged unrelated to efalizumab (1 patient had progressive thrombocytopenia associated with metastatic prostate cancer and the other had chronic thrombocytopenia that preceded efalizumab therapy).
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only